ÁñÁ«ÊÓƵ

[Skip to Navigation]
Sign In

April 2024 - April 2015

Decade

Year

Issue

February 2024, Vol 10, No. 2, Pages 154-264

Original Investigation

Population Attributable Risk of Advanced-Stage Breast Cancer by Race and Ethnicity

Abstract Full Text
JAMA Oncol. 2024;10(2):167-175. doi:10.1001/jamaoncol.2023.5242

This cohort study evaluates the population attributable risk proportions for advanced-stage breast cancer associated with clinical risk factors among routinely screened women by race and ethnicity.

Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2024;10(2):176-184. doi:10.1001/jamaoncol.2023.5248

This randomized clinical trial compares the effectiveness of 2 physical activities of different modalities and intensities on subjective sleep quality, physical and psychological outcomes, and survival in patients with advanced lung cancer.

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2024;10(2):185-192. doi:10.1001/jamaoncol.2023.5410

This randomized clinical trial evaluates the efficacy and safety of adding pembrolizumab to platinum-based chemotherapy with or without bevacizumab in women with cervical carcinoma that was not amenable to curative treatment.

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial

Abstract Full Text
open access has audio
JAMA Oncol. 2024;10(2):193-201. doi:10.1001/jamaoncol.2023.5424

This randomized clinical trial examines the efficacy of adding atezolizumab to treatment with carboplatin in patients with metastatic triple-negative breast cancer (TNBC), and the clinical or molecular correlates associated with disease response.

Abandonment of Routine Radiotherapy for Nonlocally Advanced Rectal Cancer and Oncological Outcomes

Abstract Full Text
JAMA Oncol. 2024;10(2):202-211. doi:10.1001/jamaoncol.2023.5444

This cross-sectional study examines the association of decreased use of neoadjuvant radiotherapy with cancer-related outcomes and overall survival.

Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing

Abstract Full Text
open access
JAMA Oncol. 2024;10(2):212-219. doi:10.1001/jamaoncol.2023.5586

This diagnostic study assesses the outcomes of paired DNA and RNA testing on detection of disease-causing germline genetic variants and resolution of variants of uncertain significance.

Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant: An Open-Label Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2024;10(2):220-226. doi:10.1001/jamaoncol.2023.5757

This randomized clinical trial examines whether repeated infusions of mesenchymal stem cells during the early stage after haploidentical hematopoietic stem cell transplant decreases the incidence of severe chronic graft-vs-host disease.

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2024;10(2):227-235. doi:10.1001/jamaoncol.2023.5033

This open-label phase 2 randomized clinical trial evaluates the clinical effects and biomarker findings of treatment with neoadjuvant pembrolizumab and carboplatin plus docetaxel in patients with triple-negative breast cancer.

Brief Report

The Potential of Genetics in Identifying Women at Lower Risk of Breast Cancer

Abstract Full Text
open access
JAMA Oncol. 2024;10(2):236-239. doi:10.1001/jamaoncol.2023.5468

This case-control study assesses breast cancer incidence among women at low genetic risk compared with women at average risk, evaluating the potential to delay mammography on the basis of genetic risk stratification.

Research Letter

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

Abstract Full Text
open access
JAMA Oncol. 2024;10(2):256-258. doi:10.1001/jamaoncol.2023.5573

This cohort study compares glucagon-like peptide 1 receptor agonists (GLP-1RAs) with 7 non–GLP-1RA antidiabetics among drug-naive patients with type 2 diabetes.

Review

Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2024;10(2):240-248. doi:10.1001/jamaoncol.2023.5269

This narrative review considers the current evidence and ongoing trials of neoadjuvant or prenephrectomy immune checkpoint inhibitor therapy in patients with locally advanced and metastatic renal cell carcinoma.

Rapid Advances in Resectable Non–Small Cell Lung Cancer: A Narrative Review

Abstract Full Text
has active quiz
JAMA Oncol. 2024;10(2):249-255. doi:10.1001/jamaoncol.2023.5276

This narrative review examines the rapidity of development and introduction of a broad array of novel options for the treatment of patients with resectable early-stage non–small cell lung cancer.

Viewpoint

Addressing the Drug-Shortage Crisis in Oncology

Abstract Full Text
JAMA Oncol. 2024;10(2):155-156. doi:10.1001/jamaoncol.2023.5722

This Viewpoint offers strategies for addressing shortages in essential chemotherapeutic drugs.

Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewindâ€

Abstract Full Text
JAMA Oncol. 2024;10(2):157-158. doi:10.1001/jamaoncol.2023.5725

This Viewpoint discusses the causes and consequences of Medicaid unwinding and disenrollment and proposes solutions to minimize disenrollment and improve coverage uptake and health care access.

The Long Behavioral Tail of the COVID-19 Pandemic—A Cancer Control Perspective

Abstract Full Text
JAMA Oncol. 2024;10(2):159-160. doi:10.1001/jamaoncol.2023.5595

This Viewpoint discusses the impact of the COVID-19 public health emergency on the trajectory of cancer deaths.

Editorial

Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For

Abstract Full Text
JAMA Oncol. 2024;10(2):163-165. doi:10.1001/jamaoncol.2023.5324
Cancer Care Chronicles

Reflections on My Journey With Cancer—Unexpected Insights From Game Night

Abstract Full Text
JAMA Oncol. 2024;10(2):161-162. doi:10.1001/jamaoncol.2023.5583

This essay describes reflections on the author’s journey with cancer through unexpected insights from a casual game night with friends.

Poetry and Oncology

Plutonic Cancer

Abstract Full Text
JAMA Oncol. 2024;10(2):264. doi:10.1001/jamaoncol.2023.5580
Comment & Response

Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases

Abstract Full Text
JAMA Oncol. 2024;10(2):258-259. doi:10.1001/jamaoncol.2023.6060

Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases

Abstract Full Text
JAMA Oncol. 2024;10(2):259. doi:10.1001/jamaoncol.2023.6077

Nontumor Cells in Tumor Samples Bias Expression-Based Models

Abstract Full Text
JAMA Oncol. 2024;10(2):259-260. doi:10.1001/jamaoncol.2023.6117

Nontumor Cells in Tumor Samples Bias Expression-Based Models—Reply

Abstract Full Text
JAMA Oncol. 2024;10(2):260-261. doi:10.1001/jamaoncol.2023.6120
Correction

Error in Byline

Abstract Full Text
free access
JAMA Oncol. 2024;10(2):261. doi:10.1001/jamaoncol.2023.6616
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2024;10(2):154. doi:10.1001/jamaoncol.2023.4632
×